Formulation & Delivery US 2024
For Fiscal Year Ending December 31, 2023
Sign up today and receive company updates straight to your inbox.
Our Investor Fact Sheet provides quick-hit details about how we're improving prescription drug safety through chemistry. Quickly learn about who we are, our technology platforms, our targeted therapy areas, and more.
Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the fear of and the potential for opioid misuse, abuse and overdose. Our current development pipeline includes two new drug platforms - an abuse-resistant prodrug technology – the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection prodrug technology - the Multi-Pill Abuse Resistant, or the MPAR™ platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR™ platform when combined with our TAAP prodrugs is designed not only to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat is an ingredient in our overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Ensysce Biosciences, Inc.
7946 Ivanhoe Ave
Suite 201
La Jolla, CA 92037
T: 858-263-4196
info@ensysce.com
MZ North America
5055 Avenida Encinas
Suite 130
Carlsbad, CA 92008
T: 203-741-8811
Shannon Devine
shannon@mzgroup.us
Continental Stock Transfer & Trust Company
1 State Street
30th Floor
New York, NY 10004-1561
T: 212-509-4000
Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.